Eisler Capital (Uk) Ltd. Gilead Sciences, Inc. Call Options Transaction History

Eisler Capital (Uk) Ltd.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $1.02 Million - $1.28 Million	15,250 Added 20.36%	90,143 $7.56 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $454,932 - $525,027	7,204 Added 10.64%	74,893 $5.14 Million
Q1 2024 May 14, 2024	SELL	$71.58 - $87.29 $371,285 - $452,773	-5,187 Reduced 7.12%	67,689 $4.96 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $4.63 Million - $5.25 Million	63,233 Added 655.74%	72,876 $5.9 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $1.87 Million - $2.05 Million	-25,357 Reduced 72.45%	9,643 $722,000
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $2.66 Million - $3.03 Million	35,000 New	35,000 $2.7 Million

1,930

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Eisler Capital (Uk) Ltd., based on Form 13F filings with the SEC.

Stay updated on Eisler Capital (Uk) Ltd. with notifications on news.